Literature DB >> 16248284

Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.

Nikolai G Rainov1, Ariane Söling.   

Abstract

KS Biomedix (formerly Avicenna Medica; now a subsidiary of the Xenova group) and Nycomed, together with Japanese licensee Sosei and Chinese licensee PharmaEngine, are developing TransMID, a transferrin-mediated diphtheria toxin delivery system for the potential treatment of adult, recurrent, inoperable, high-grade glioma (as TransMID-107R). It is also under investigation for other forms of brain cancer, including early brain cancer (as TransMID-107N), metastatic brain cancer (as TransMID-107M) and pediatric brain cancer (as TransMID-107P). TransMID is currently undergoing phase III clinical trials.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16248284

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  5 in total

1.  Evaluation of Nonferrous Metals as Potential In Vivo Tracers of Transferrin-Based Therapeutics.

Authors:  Hanwei Zhao; Shunhai Wang; Son N Nguyen; S Gokhan Elci; Igor A Kaltashov
Journal:  J Am Soc Mass Spectrom       Date:  2015-09-21       Impact factor: 3.109

2.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Authors:  Jeremy D Heidel; Zhongping Yu; Joanna Yi-Ching Liu; Shyam M Rele; Yongchao Liang; Ryan K Zeidan; Douglas J Kornbrust; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-22       Impact factor: 11.205

3.  Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.

Authors:  Son N Nguyen; Cedric E Bobst; Igor A Kaltashov
Journal:  Mol Pharm       Date:  2013-04-10       Impact factor: 4.939

Review 4.  Bioengineering strategies for designing targeted cancer therapies.

Authors:  Angela A Alexander-Bryant; Wendy S Vanden Berg-Foels; Xuejun Wen
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  Differential screening of phage-ab libraries by oligonucleotide microarray technology.

Authors:  Paolo Monaci; Alessandra Luzzago; Claudia Santini; Alessandra De Pra; Mirko Arcuri; Francesca Magistri; Alessandro Bellini; Helenia Ansuini; Maria Ambrosio; Virginia Ammendola; Maria Giulia Bigotti; Agostino Cirillo; Maurizio Nuzzo; Annamaria Assunta Nasti; Philippe Neuner; Laura Orsatti; Monica Pezzanera; Andrea Sbardellati; Giuseppe Silvestre; Paolo Uva; Valentina Viti; Gaetano Barbato; Stefano Colloca; Anna Demartis; Emanuele De Rinaldis; Saverio Giampaoli; Armin Lahm; Fabio Palombo; Fabio Talamo; Alessandra Vitelli; Alfredo Nicosia; Riccardo Cortese
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.